Short answer
Kymera Therapeutics, Inc. (KYMR) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $3M (down 26.1% year over year) with net income of −$82M.
Q3 2025 key financials · XBRL
- Revenue
- $3M
- −26.1% YoY · −75.9% QoQ
- Net income
- −$82M
- −31.5% YoY · −7.3% QoQ
- Operating margin
- -3346.1%
- EPS (diluted)
- −$0.94
- −13.3% YoY · +1.1% QoQ
Source: XBRL data from the Kymera Therapeutics, Inc. (KYMR) Q3 2025 10-Q on SEC EDGAR. USD.
Kymera Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: Strategic discontinuations of KT-295 and KT-474 programs in mid-2025 reduce pipeline breadth and may delay development timelines
- Updated risk: Increased operating expenses and net loss of $224.4M for nine months ended Sept 30, 2025 vs $153.1M prior year due to advancing clinical activities
- Regulatory risk: Clinical holds possible if submitted preclinical/manufacturing data not accepted by FDA, delaying clinical trial initiation
- Market risk: Dependency on early-stage STAT6 and other preclinical programs for near-term clinical advancement impacts timeline and visibility to revenue
- Financial risk: $978.7M cash and equivalents as of Sept 30, 2025 expected to fund operations into H2 2028, but capital needs may rise with expanded clinical development
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Kymera Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.